First Analysis
QuietFiled to raiseChicago, ILEnterprise software, Biotech & pharma, Medical devicesLast fund filed 2023
5 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| First Analysis Fund XIV (Cayman)Filed to raise in 2023, with no closing reported yet. | 2023 | $100M | $0 | 0 |
| First Analysis Fund XIV-AFiled to raise in 2023, with no closing reported yet. | 2023 | $100M | $0 | 0 |
| First Analysis Fund XIVFiled to raise in 2023, with no closing reported yet. | 2023 | $100M | $0 | 0 |
| FIRST ANALYSIS FUND XII | June 2017 | $65M | $65M | 60 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 5 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Corey Greendale | Quiet | Enterprise software | 3 | 0 |
Categories of First Analysis’s own portfolio companies, based on 6 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of First Analysis’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| ARCH Venture Partners | 1 | Sana Biotechnology |
| Baird Venture Partners | 1 | Focus IP |
| Cofounders Capital | 1 | Cycle Labs |
| Grand Ventures | 1 |
| First Analysis Fund XII (Cayman)Filed to raise in 2017, with no closing reported yet. | 2017 | $115M | $0 | 0 |
| F. Nicklin, Jr. | Quiet | None listed | 0 | 0 |
| Howard Smith | Quiet | Enterprise software | 7 | 0 |
| James MacDonald | Quiet | Biotech & pharma | 5 | 0 |
| Matthew NicklinNot on the current fund | Quiet | Enterprise software | 1 | 0 |
| Tracy Marshbanks | Quiet | Medical devices | 4 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Blue Medora |
| Iyengar Capital Partners | 1 | CSA Medical |
| JMI Equity | 1 | RECSOLU |
| Lewis & Clark | 1 | Blue Medora |
| SV Life Sciences | 1 | CSA Medical |
A shared board seat: a company where filings name a First Analysis partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.